Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | BMC Cancer |
| MU Faculty or unit | |
| Citation | |
| Web | https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5 |
| Doi | http://dx.doi.org/10.1186/s12885-018-4966-5 |
| Keywords | Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma |
| Description | For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies. |
| Related projects: |